The 2020 ACLS guidelines provide recommendations on the medication-specific management for arrhythmias including wide-complex tachycardia, regular narrow-complex tachycardia, atrial fibrillation/flutter, and bradycardia [1]. There are also our 2020 ACLS guideline summaries on vasopressor and non-vasopressor medications used during cardiac arrest and toxicology-related conditions.
Wide-complex tachycardia (WCT)
Wide-complex tachycardia | Medication(s) | Evidence |
---|---|---|
Hemodynamically stable | Adenosine | COR 2b, LOE B-NR |
Amiodarone, procainamide, or sotalol | COR 2b, LOE B-R | |
NOTE: Verapamil is harmful | COR 3, LOE B-NR | |
Polymorphic VT with long QT (torsades de points) | Magnesium | COR 2b, LOE C-LD |
Polymorphic VT without long QT | Lidocaine or amiodarone | COR 2b, LOE C-LD |
Regular narrow-complex tachycardia
- Vagal maneuvers (COR 1, LOE B-R)
- Adenosine (COR 1, LOE B-R)
- Diltiazem or verapamil (COR 2a, LOE B-R)
- Beta-blockers (COR 2a, LOE C-LD)
Atrial fibrillation/flutter with rapid ventricular rate
- Beta-blocker or diltiazem or verapamil (COR 1, LOE B-NR)
- Amiodarone (COR 2a, LOE B-NR)
Bradycardia
- Treat reversible causes (COE 1, LOE C-EO)
- Atropine if hemodynamic compromise (COR 2a, LOE B-NR)
- Epinephrine or transcutaneous pacing if unresponsive to atropine (COR 2b, LOE C-LD)
Reference
Author information
The post 2020 ACLS Guidelines on Medications for Management of Specific Arrhythmias appeared first on ALiEM.